Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain

NCT00804375 | Unknown Phase 2

• 2 other identifiers: 2PX-SP-02SMR-1850
• Study Type: interventional
• Target: 150
• Locations: 5 countries
• Sites: 19

Brief Summary

Primary: To compare the analgesic effect over 12 weeks of topical 2PX in stump pain. Secondary: To prospectively measure other efficacy and safety variables of topical 2PX in stump pain. Exploratory analyses will be performed to measure efficacy and safety variables of topical 2PX in phantom pain

Conditions

Stump Pain

Keywords

stump pain

Outcome Measures

Primary Outcomes (1)

• Average (stump) Pain Intensity (AsPI): and recorded in the diary in response to the question: 'What was your average stump pain intensity over the past 24 hours?' on a 100 mm VAS (0 = no pain, 100 = worst pain imaginable).

  will be measured each evening (at least 1 hour after taking off the prosthesis, if applicable, and immediately prior to administering the evening dose of study medication)

Secondary Outcomes (1)

• Worst (stump) Pain Intensity (WsPI): recorded in the diary in response to the question: 'What was your worst stump pain level during the past 24 hours?' on a 100 mm VAS (0 = no pain, 100 = worst pain imaginable).

  will be measured each evening (at least 1 hour after taking off the prosthesis, if applicable, and immediately prior to administering the evening dose of study medication

Study Arms (2)

2PX

EXPERIMENTAL

Pain medication

Drug: 2PX

placebo

PLACEBO COMPARATOR

placebo

Drug: Placebo

Interventions

2PX DRUG

cutaneous solution to be applied twice daily for 84 days

2PX

Placebo DRUG

cutaneous solution to be applied twice daily for 84 days

placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Lower limb amputation at least 6 months prior to Visit 1. Amputation must be transtibial, transfemoral or through the knee. For patients with transfemoral amputation, the point of amputation must be ≥10 cm from the inguinal region.
• Presenting with moderate-to-severe stump pain. For the purpose of this study, the following criteria must all apply:
• Stump pain commencing post amputation and continues at Visit 1 despite continued use of analgesic medication
• Stump pain present on a daily basis
• Stump pain intensity as Average stump Pain Intensity (AsPI) ≥40 on 100 mm VAS at Screening
• Stump pain intensity at the randomisation visit: Mean (over the 7 day run-in period) AsPI rating ≥40 on a 100 mm VAS.
• Pain at the site of the extremity amputation. The pain is located mainly in the stump itself. (Patients with concurrent phantom pain may be enrolled in the study.)
• Stump pain persists despite proper healing of the stump
• Outpatients, aged 18 years and above
• Underlying therapy (e.g., rehabilitation procedures, analgesia, physio-therapy, spinal cord stimulation (except for topical or subcutaneous local analgesics)) may be continued throughout the duration of the study, if the regimen has been stable during the 4 weeks immediately prior to Visit 1. If underlying therapy is continued during the study the regimen must be maintained for the duration of the study.
• Written informed consent

You may not qualify if:

• Patients with forefoot amputations alone are excluded from participation.
• Patients who have received treatment with any topical or subcutaneously administered analgesic agent for stump or phantom pain in the 4 weeks prior to study entry (i.e. Visit 1).
• Underlying therapy (e.g., rehabilitation procedures, analgesia, physio-therapy, spinal cord stimulation) is not permitted if the regimen has not been stable in the 4 weeks immediately prior to Visit 1.
• After the 7 day run-in phase: patients taking any new or changing the dose of any underlying analgesic medication (except for rescue medication as defined in this protocol).
• Patients with open wounds, burns or other non-intact skin at site(s) of study drug administration (unhealed stumps).
• Patients with significant discomfort from their prosthesis limiting use of the prosthesis. Use of a prosthesis is not a requirement for participation in the study.
• Pregnancy
• Female patients of childbearing potential unwilling to use adequate contraception measures throughout the duration of the study. For the purpose of this study, adequate contraception is defined as:
• oral, injected or implanted hormonal methods of contraception; OR
• placement of an intrauterine device (IUD) or intrauterine system (IUS); OR
• barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository Note: Male sterilization or abstinence are not acceptable methods of birth control and would preclude enrolment in the study.
• Note: For post-menopausal women: less than 12 months since the last spontaneous menstrual bleeding will exclude the patient unless they are willing to utilise acceptable methods of contraception for the duration of the study.
• Breast-feeding/lactating mothers
• Any active malignant disease (except basal cell carcinoma; BCC)
• Patients who have previously received 2PX.

Sponsors & Collaborators

• Smerud Medical Research International AS: lead
• SantoSolve AS: collaborator

Study Sites (19)

Site in Århus

Aarhus, Denmark

COMPLETED

Site in Herlev

Herlev, Denmark

COMPLETED

Site in Hvidovre

Hvidovre, Denmark

COMPLETED

Site in Wiesbaden

Wiesbaden, Germany

RECRUITING

Site in Ålesund

Ålesund, Norway

COMPLETED

Site in Hamar

Hamar, Norway

COMPLETED

Site in Oslo

Oslo, Norway

COMPLETED

Site in Stavern

Stavern, Norway

COMPLETED

Site in St. Petersburg

Saint Petersburg, Russia

RECRUITING

Site in St.Petersburg

Saint Petersburg, Russia

RECRUITING

Site in Belfast

Belfast, United Kingdom

COMPLETED

Site in Birmingham

Birmingham, United Kingdom

COMPLETED

Site in Edinburgh

Edinburgh, United Kingdom

COMPLETED

Site in Glasgow

Glasgow, United Kingdom

COMPLETED

Site in Hammersmith

Hammersmith, United Kingdom

COMPLETED

Site in Crystal Palace

London, United Kingdom

COMPLETED

Site in Manchester

Manchester, United Kingdom

COMPLETED

Site in Middlesborough

Middlesbrough, United Kingdom

COMPLETED

Site in Newcastle

Newcastle, United Kingdom

COMPLETED

Study Officials

• Lone Nikolajsen, MD

  Aarhus University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Robert Macnair, PhD

CONTACT

+44 1357 523481; bob.macnair@smerud.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: December 5, 2008
• First Posted: December 8, 2008
• Study Start: December 1, 2008
• Primary Completion: June 1, 2010
• Study Completion: June 1, 2010
• Last Updated: March 24, 2010

Record last verified: 2010-03

Locations

DE (1); NO (4); RU (2); DK (3); GB (9)